Universität zu Köln

2018

Pfister, R., Achenbach, S., Boenner, F., Mueller, O. J., Hallek, M., Kochanek, M., Bokemeyer, C., Weissinger, F., Lueftner, D., Baldus, S. and Kelm, M. (2018). Comments on the 2016 position paper of the European Society of Cardiology (ESC) on cardiovascular complications of oncological treatment. Kardiologe, 12 (1). S. 19 - 26. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1864-9726

2016

Bloch, W., Baumann, F., Zimmer, P., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Tesch, H., Schuetz, F., Lueftner, D. and Jackisch, C. (2016). Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER plus women - Results of the 3rd interim analysis of BRAWO. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Tesch, H., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2016). Results of the 3rd interim analysis of the non-interventional trial BRAWO - Subanalysis of patients < 70 years and >= 70 years. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

2015

Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F. and Jackisch, C. (2015). Disease characteristics of subgroup patients treated with everolimus plus exemestane for < 12 months, >= 12 to < 18months, and >= 18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Eur. J. Cancer, 51. S. S288 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Tesch, H., Grischke, E-M, Fasching, P., Decker, T., Uleer, C., Schneeweiss, A., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2015). Results of the 3rd interim analysis of BRAWO - breast cancer treatment with everolimus and exemestane for ER plus women. Oncol. Res. Treat., 38. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262